These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 10399198)

  • 1. Adaptive design improvements in the continual reassessment method for phase I studies.
    Heyd JM; Carlin BP
    Stat Med; 1999 Jun; 18(11):1307-21. PubMed ID: 10399198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian three-parameter logistic model for early- and late-onset DLTs in oncology Phase I studies.
    Zheng W; Zhao Y; Lu Y; Miao H; Liu H
    J Biopharm Stat; 2016; 26(2):339-51. PubMed ID: 25629564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The continual reassessment method in cancer phase I clinical trials: a simulation study.
    Chevret S
    Stat Med; 1993 Jun; 12(12):1093-108. PubMed ID: 8210815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies.
    Zohar S; Chevret S
    Stat Med; 2001 Oct; 20(19):2827-43. PubMed ID: 11568943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data.
    James GD; Symeonides SN; Marshall J; Young J; Clack G
    BMC Cancer; 2016 Aug; 16(1):703. PubMed ID: 27581751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to design a dose-finding study using the continual reassessment method.
    Wheeler GM; Mander AP; Bedding A; Brock K; Cornelius V; Grieve AP; Jaki T; Love SB; Odondi L; Weir CJ; Yap C; Bond SJ
    BMC Med Res Methodol; 2019 Jan; 19(1):18. PubMed ID: 30658575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical controversies in clinical research: building the bridge to phase II-efficacy estimation in dose-expansion cohorts.
    Boonstra PS; Braun TM; Taylor JMG; Kidwell KM; Bellile EL; Daignault S; Zhao L; Griffith KA; Lawrence TS; Kalemkerian GP; Schipper MJ
    Ann Oncol; 2017 Jul; 28(7):1427-1435. PubMed ID: 28200082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continual reassessment methods in phase I trials of the combination of two drugs in oncology.
    Kramar A; Lebecq A; Candalh E
    Stat Med; 1999 Jul; 18(14):1849-64. PubMed ID: 10407256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of phase I cancer clinical trial designs.
    Ahn C
    Stat Med; 1998 Jul; 17(14):1537-49. PubMed ID: 9699228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
    James GD; Symeonides S; Marshall J; Young J; Clack G
    BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials.
    Pan H; Yuan Y
    Stat Med; 2017 Jan; 36(2):266-279. PubMed ID: 26991076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials.
    Ishizuka N; Ohashi Y
    Stat Med; 2001 Sep 15-30; 20(17-18):2661-81. PubMed ID: 11523075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-dose-cohort designs in cancer phase I trials.
    Huang B; Chappell R
    Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical modifications of the continual reassessment method for phase I cancer clinical trials.
    Faries D
    J Biopharm Stat; 1994 Jul; 4(2):147-64. PubMed ID: 7951271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some practical improvements in the continual reassessment method for phase I studies.
    Goodman SN; Zahurak ML; Piantadosi S
    Stat Med; 1995 Jun; 14(11):1149-61. PubMed ID: 7667557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A two-stage dose selection strategy in phase I trials with wide dose ranges.
    Wang O; Faries DE
    J Biopharm Stat; 2000 Aug; 10(3):319-33. PubMed ID: 10959914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.
    Iasonos A; Wilton AS; Riedel ER; Seshan VE; Spriggs DR
    Clin Trials; 2008; 5(5):465-77. PubMed ID: 18827039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.